Jiangsu Lianhuan Pharmaceutical Co Ltd Asset Resilience Ratio
Jiangsu Lianhuan Pharmaceutical Co Ltd asset resilience ratio. Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2020)
Asset resilience ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2020. This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Lianhuan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600513 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥81.18K | 0.0% |
| Total Liquid Assets | CN¥81.18K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Lianhuan Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Lianhuan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Lianhuan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Jiangsu Lianhuan Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2000–2020)
Jiangsu Lianhuan Pharmaceutical Co Ltd asset resilience ratio by year from 2000 to 2020. The table below shows the annual Asset Resilience Ratio data for Jiangsu Lianhuan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.00% | CN¥38.43K ≈ $5.62K |
CN¥2.05 Billion ≈ $299.84 Million |
0.00pp |
| 2019-12-31 | 0.00% | CN¥45.18K ≈ $6.61K |
CN¥1.89 Billion ≈ $276.51 Million |
0.00pp |
| 2018-12-31 | 0.00% | CN¥41.85K ≈ $6.12K |
CN¥1.42 Billion ≈ $207.80 Million |
0.00pp |
| 2017-12-31 | 0.00% | CN¥51.48K ≈ $7.53K |
CN¥1.16 Billion ≈ $170.40 Million |
0.00pp |
| 2016-12-31 | 0.00% | CN¥52.29K ≈ $7.65K |
CN¥1.07 Billion ≈ $156.03 Million |
0.00pp |
| 2015-12-31 | 0.01% | CN¥54.45K ≈ $7.97K |
CN¥1.00 Billion ≈ $146.41 Million |
-0.04pp |
| 2014-12-31 | 0.05% | CN¥305.78K ≈ $44.75K |
CN¥658.96 Million ≈ $96.43 Million |
+0.02pp |
| 2013-12-31 | 0.03% | CN¥179.80K ≈ $26.31K |
CN¥649.48 Million ≈ $95.04 Million |
-0.02pp |
| 2012-12-31 | 0.05% | CN¥218.82K ≈ $32.02K |
CN¥443.21 Million ≈ $64.86 Million |
0.00pp |
| 2011-12-31 | 0.05% | CN¥218.27K ≈ $31.94K |
CN¥418.52 Million ≈ $61.24 Million |
-0.01pp |
| 2010-12-31 | 0.06% | CN¥234.78K ≈ $34.36K |
CN¥401.08 Million ≈ $58.69 Million |
-0.07pp |
| 2009-12-31 | 0.13% | CN¥510.75K ≈ $74.74K |
CN¥383.36 Million ≈ $56.10 Million |
+0.08pp |
| 2008-12-31 | 0.06% | CN¥208.76K ≈ $30.55K |
CN¥359.66 Million ≈ $52.63 Million |
+0.00pp |
| 2007-12-31 | 0.06% | CN¥206.85K ≈ $30.27K |
CN¥357.66 Million ≈ $52.34 Million |
+0.03pp |
| 2006-12-31 | 0.03% | CN¥94.40K ≈ $13.81K |
CN¥335.84 Million ≈ $49.14 Million |
-0.10pp |
| 2004-12-31 | 0.13% | CN¥400.00K ≈ $58.53K |
CN¥312.05 Million ≈ $45.66 Million |
-0.01pp |
| 2003-12-31 | 0.14% | CN¥400.00K ≈ $58.53K |
CN¥293.21 Million ≈ $42.91 Million |
+0.10pp |
| 2000-12-31 | 0.03% | CN¥35.33K ≈ $5.17K |
CN¥103.67 Million ≈ $15.17 Million |
-- |
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more